Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease
Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether…Exercise and levodopa metabolism in Parkinson disease
Objective: The aim of our paper was to assess if standard physical exercise may change pharmacokinetics of levodopa/benserazide in patients with and without prior exposure…Screening risk of falls in Parkinson’s disease population living in underserved areas
Objective: To verify the feasibility of the Balance-App to assess the risk of falls in the PD population living in underserved areas. Background: The screening…The prevalence and clinical features of GBA-related Parkinson’s disease in a Slovak patient cohort
Objective: The aim of our study was to determine the prevalence and clinical characteristics of Slovak GBA-related patients with Parkinson's disease (PwP). Background: GBA variants…A comparison of national data on Parkinson’s disease mortality between the USA and UK
Objective: To evaluate recent mortality trends in Parkinson’s Disease (PD) between the United States of America (USA) and the United Kingdom (UK) per national healthcare…Detection of freezing of gait in people with Parkinson’s disease using novel deep learning approaches.
Objective: To detect freezing of gait (FOG) in people with Parksinson’s disease using three novel deep learning approaches. Background: FOG is one of the most…Improvements in Parkinson’s disease motor complications after treatment with opicapone: results from the OPTI-ON study
Objective: To describe motor complications as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part IV in participants from the Opicapone Treatment…Recommendations to tackle under-recognition and under-treatment of sialorrhea in Parkinson’s Disease: Is it time for a paradigm shift?
Objective: To leverage patient survey data and expert opinion to develop recommendations for managing sialorrhea in patients with Parkinson’s disease (PD). Background: Sialorrhea, or drooling,…Long-term evolution of advanced Parkinson’s disease burden: second interim results from the international PROSPECT observational study
Objective: To evaluate the long-term evolution of clinical and economic outcomes and treatment patterns of patients with advanced Parkinson’s disease (PD) who have symptoms that…Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation
Objective: To characterize the relationship between anticholinergic burden (ACB), mild cognitive impairment (MCI), and its underlying cholinergic pathology. Background: MCI is a common phenomenon in…
- « Previous Page
- 1
- …
- 393
- 394
- 395
- 396
- 397
- …
- 553
- Next Page »